Form 4: Director Chan Heng Fai Ambrose Reports Sale of Impact Biomedical Inc. Shares
SEC Form 4
Director Chan Heng Fai Ambrose reports the sale of 351,555 common stock shares of Impact Biomedical Inc. by Alset International Limited, a majority-owned subsidiary of Alset Inc.
Summary
- On April 3, 2025, Alset International Limited sold 351,555 shares of Impact Biomedical Inc.'s common stock.
- The shares were sold at a weighted average price of $0.495 per share.
- The transactions occurred in multiple trades with prices ranging from $0.46 to $0.57.
- Chan Heng Fai Ambrose, a director of Impact Biomedical Inc., is the majority shareholder of Alset Inc., and the Chairman and CEO of Alset Inc.
- Alset International Limited is a majority-owned subsidiary of Alset Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a transaction without expressing positive or negative views.
Related Party Transactions
- Alset International Limited, a majority-owned subsidiary of Alset Inc. (where Chan Heng Fai Ambrose is the majority shareholder, Chairman, and CEO), sold the shares.
Stakeholder Impact
- The sale of shares may impact shareholders due to potential price fluctuations.
Key Dates
| Date | Description |
|---|---|
| 04/03/2025 | Date of transaction: Alset International Limited sold 351,555 shares of Impact Biomedical Inc. common stock. |
| 04/07/2025 | Date of report filing. |
Keywords
Impact Biomedical Inc., Chan Heng Fai Ambrose, Alset International Limited, Share Sale, Director, Form 4, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.